Keywords: Sanofi, iniparib, Ipsen, Irosustat, Breast, Endometrial, Prostate cancer

Disappointments for Sanofi’s iniparib in Ph III breast cancer study and Ipsen’s Irosustat

Article | 08 June 2011

Print This

French drug major Sanofi (Euronext: SAN) announced negative results from a new Phase III study of iniparib (BSI-201) in metastatic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in